FSD Pharma Reports Second Quarter 2020 Financial Results

TORONTO–(BUSINESS WIRE)– #FSDDF–FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition and results of operations (“MD&A”) for the three months ended June 30, 2020 have been filed and can be viewed on the Company’s SEDAR profile at www.sedar.com. FSD Pharma also provided a business update: The Phase 1 first-in-human safety and tolerability study with ultramicronized-palmitoylethanolam

READ MORE: http://www.businesswire.com/news/home/20200807005510/en/FSD-Pharma-Reports-Quarter-2020-Financial-Results/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB7TDOU5CqE9t5WwBA1inzlrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3kCXJZE-1b1nXn968wYfofVIbE9ZC1pD3bt6lQgRU5j6g==